ReviewWorld journal of surgical oncology2016
Tumour-induced osteomalacia: a literature review and a case report.
Review in World journal of surgical oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 73 citations in OpenAlex.
- Phosphaturic mesenchymal tumour, connective tissue variant: a rare radiological presentation involving the radius mimicking fibrous dysplasia with oncogenic rickets.Skeletal radiology · 2026Article
- Burosumab for adults with tumor-induced osteomalacia in China.Endocrine connections · 2026Article
- Burosumab in Unidentifiable Tumor-Induced Osteomalacia.Clinical case reports · 2026Article
- Challenges in Evaluation and Management in Tumor-Induced Osteomalacia: A Retrospective Institutional and Literature-Based Scoping Review in Korean Patients.Journal of bone metabolism · 2025Article
- Biochemical evaluation of X-linked hypophosphatemia and tumor-induced osteomalacia: insights into diagnosis and management.Frontiers in endocrinology · 2025Review
- A Rare Case of Phosphaturic Mesenchymal Tumor Distal Femur in a Young Female.Journal of orthopaedic case reports · 2024Article
- FGF23-secreting sinonasal tumour presenting with acute subdural haemorrhage and tumour-induced osteomalacia.BMJ case reports · 2024Article
- Unusual presentation of tumor-induced osteomalacia mismanaged due to misdiagnosis: A literature review based on a case report.Clinical case reports · 2024Article
- A case of hyperparathyroidism secondary to tumor-induced osteomalacia.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2023Article
- Unusual phosphaturic mesenchymal tumor mimicking osteoid osteoma.Radiology case reports · 2023Article
- Tumour induced osteopenia due to phosphaturic mesenchymal sinonasal tumour presenting with delayed onset insufficiency fractures.Journal of radiology case reports · 2023Article
- Global guidance for the recognition, diagnosis, and management of tumor-induced osteomalacia.Journal of internal medicine · 2023Review
- Challenging case of tumour-induced osteomalacia.BMJ case reports · 2022Article
- Diagnosis and Management of Tumor-induced Osteomalacia: Perspectives From Clinical Experience.Journal of the Endocrine Society · 2021Article
- Extended Whole-body Ga-68 DOTATATE PET-CT in evaluating Tumour-Induced Osteomalacia: Case report and review of literature.Nuclear medicine and molecular imaging · 2021Article
- Hypophosphatemia and FGF23 tumor-induced osteomalacia in two cases of metastatic breast cancer.Clinical nephrology · 2021Article
- Tumor-Induced Osteomalacia.Calcified tissue international · 2021Review
- Clinical Image: Multiple pathological fractures in a middle-aged woman: A rheumatologist's challenge.ACR open rheumatology · 2020Article
- Oncogenic Osteomalacia with Elevated Fibroblast Growth Factor 23: A Rare Case of Paranasal Sinus Tumor Onset.Cureus · 2019Article
- Tumor-induced osteomalacia: experience from three tertiary care centers in India.Endocrine connections · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumour-induced osteomalacia (TIO) is a rare paraneoplastic syndrome characterised by severe hypophosphataemia and osteomalacia, with renal phosphate wasting that occurs in association with tumour. The epidemiology likewise aetiology is not known. The clinical presentation of TIO includes bone fractures, bone and muscular pains, and sometimes height and weight loss. TIO may be associated with mesenchymal tumours which may be benign or malignant in rare cases. Mesenchymal tumour itself may be related to fibroblast growth factor 23 (FGF23), which is responsible for hypophosphataemia and phosphaturia occurring in this paraneoplastic syndrome. Hypophosphataemia, phosphaturia and elevated alkaline phosphatase are the main laboratory readings that may lead to more precise investigations and better diagnosis. Finding the tumour can be a major diagnostic challenge and may involve total body magnetic resonance imaging, computed tomography and scintigraphy using radiolabelled somatostatin analogue. The treatment of choice for TIO is resection of a tumour with a wide margin to insure complete tumour removal, as recurrences of these tumours have been reported. We provide here an overview on the current available TIO case reports and review the best practices that may lead to earlier recognition of TIO and the subsequent treatment thereof, even though biochemical background and the long-term prognosis of the disease are not well understood. This review also includes a 4-year-long history of a patient that featured muscular pains, weakness and multiple stress fractures localised in the hips and vertebra with subsequent recovery after tumour resection. Because the occurrence of such a condition is rare, it may take years to correctly diagnose the disease, as is reported in this case report.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.